Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.
about
Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and BenefitsVolumetric modulated arc therapy: a review of current literature and clinical use in practice.A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum FollInternational Conference on Advances in Radiation Oncology (ICARO): outcomes of an IAEA meeting.Dose mapping sensitivity to deformable registration uncertainties in fractionated radiotherapy - applied to prostate proton treatmentsClinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR).Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy.Hypofractionated external-beam radiotherapy for prostate cancer.Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy.Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cellsRectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.Stereotactic body radiation therapy for prostate cancer.Carbogen gas and radiotherapy outcomes in prostate cancer.Evolution of advanced technologies in prostate cancer radiotherapy.Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways.Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study.Image-guided hypofractionated radiotherapy in low-risk prostate cancer patients.Hypofractionated proton therapy for prostate cancer: dose delivery uncertainty due to interfractional motion.Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques.Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer.Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results.Reducing errors in prostate tracking with an improved fiducial implantation protocol for CyberKnife based stereotactic body radiotherapy (SBRT).
P2860
Q26998991-FB3B2E28-3989-482C-A1E8-87597EFB8EA3Q30461426-728429E6-604D-497E-9DC7-8F1012EBF734Q34510485-8CBEA87D-8299-4965-800D-EF5CA772376BQ34593033-B10C459A-5A2B-4FA2-B4ED-5582973ACFFAQ34773793-9CFF7F2F-4567-4B97-8E18-A5C0203434E0Q35686316-9263AE71-DB55-4312-97A9-A449751AD905Q36551293-E77013C7-BE8C-41D7-A9C3-2AC4DED3E109Q36711751-A0231C34-AD54-4FE6-B0A1-6427BDD69394Q37546045-EC8A4762-EE6F-4B39-8E29-7EC271233E5AQ37620420-C201D71D-67B9-4FFA-A069-354AF9AFDD59Q37725623-0E1E61A6-6E8A-4C40-A46F-3CD1B02F2C59Q37932543-20CAD945-ACE4-4CFF-A473-4EC395F54124Q38078362-180BF991-E4D4-4A35-9805-C028958A2A28Q38135708-A6DEB740-D682-4D71-B888-BD9EE624387CQ38989588-8EAD2BA7-E118-458D-A8C4-DD8D57F3DA20Q39456165-CA1DD834-3128-49EA-943A-846861FDEDF9Q39504371-5E6CFE94-B112-4ABB-A83F-C53E6B83FB9AQ41497799-2A7B589F-2C89-4CBA-A464-FC7F2E6EA840Q47362487-B9BC3B84-4CF9-4147-B0AD-777B83AF2F3EQ47911220-1C65EEF4-2B8F-45B7-A2AA-6BF9AB0ACF94Q53274295-428DB96B-73C3-43B5-9FC2-8BA2E9EF7233Q55501070-03C3C6AF-38D0-4C31-8FC2-BEF129366855
P2860
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.
@en
type
label
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.
@en
prefLabel
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.
@en
P2860
P1476
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.
@en
P2093
Mark Ritter
P2860
P304
P356
10.1016/J.SEMRADONC.2008.04.007
P577
2008-10-01T00:00:00Z